KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
Before Oct 1, 2027 71%-15.0ptEn tête parmi 5 options
Qualite du marche
33 / 100
Faible qualitéVolume 24h
158,7 €
Liquidité
179,2 €
Faible liquiditéSpread
8.0 pt
Spread largeDonnées du marché
Mis à jour il y a 10 minutes
19 août 26, 22:001 oct. 27, 3:59
Tendances
0%
0%
0%
0%
Règles
If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing the named outcome, then the market resolves to Yes.
Settles via:Food and Drug Administration
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Marchés ouverts
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.3pt96%
- Yes+0.3pt4%
- Volume total
- 15,3 M €
- Volume 24h
- 14,5 k €
KALSHIMeasles cases in 2026?
- Above 300098%
- Above 4000+2.0pt87%
- Above 6000+4.0pt30%
+2 résultats de plus
- Volume total
- 807,4 k €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+1.0pt69%
- June 30,-9.0pt12%
- Volume total
- 40,9 k €
- Volume 24h
- 1,9 k €
POLYMARKETHow many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
- Fewer than 20+14.0pt39.3%
- 20 to 34+17.0pt37.4%
- 35 to 49-12.0pt14.9%
KALSHIWhich countries will report an Ebola case in 2026?
- South Sudan56%
- Burundi35%
- Rwanda30%
+13 résultats de plus
- Volume total
- 293 k €
- Volume 24h
- 1,2 k €
POLYMARKETMeasles cases in U.S. in 2026?
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
- ↑2k+0.2pt100%
+9 résultats de plus
- Which countries will report an Ebola disease case before October?
- Ebola pandemic in 2026?
- How many human screwworm cases will be reported in the United States in 2026?
- Heidi Overton confirmed as FDA Commissioner by which date?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- Which countries will have an Ebola case in 2026?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA moves BPC-157 to Category 1 by which date?
- Hantavirus vaccine in 2026?
- What will the average number of measles cases be during Trump's term?
Questions fréquentes
- Quelles sont les probabilités actuelles pour Will the FDA approve intismeran autogene (V940/mRNA-4157)? ?
- Kalshi cote Before Oct 1, 2027 à 71% au 24 août 2026.
- Quand Will the FDA approve intismeran autogene (V940/mRNA-4157)? sera-t-il résolu ?
- Will the FDA approve intismeran autogene (V940/mRNA-4157)? doit être résolu le 1 octobre 2027.
- Comment Will the FDA approve intismeran autogene (V940/mRNA-4157)? est-il réglé ?
- Kalshi règle ce marché comme suit : If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing the named outcome, then the market resolves to Yes.